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A B S T R A C T
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive
aged women and is characterized by two of the following three features: oligoovulation or anovulation,
clinical and/or biochemical signs of hyperandrogenism, or polycystic ovaries.
Summary: It has been demonstrated that PCOS includes a complex number of systemic symptoms in
addition to symptoms related to the reproductive apparatus. It has been associated with obesity,
metabolic syndrome, type 2 diabetes and an increased risk of cardiovascular disease. Several clinical and
basic studies have investigated the link between PCOS and the cardiovascular disease risk, which seems
to be due to blunted lipid/glucose metabolism, hypertension, and systemic inﬂammatory and
coagulation disorders. Therefore, the current manuscript aims to review the main ﬁndings on PCOS and
obesity/obesity-related disease (glucose derangements and cardiovascular disease risk factors).
Key message: Although there are no long-term data on the morbidity and mortality for cardiovascular
disease in PCOS, it is advisable to perform a careful metabolic and cardiovascular assessment in women
with PCOS in order to tailor the most suitable strategy to prevent cardiovascular disease.
 2016 Elsevier Ireland Ltd. All rights reserved.Contents
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Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in reproductive aged womenwith a prevalence
of 6–10% based on the National Institute of Health (NIH) criteria
and a prevalence as high as 15% when the broader Rotterdam
criteria are used. PCOS is characterized by androgen excess, oligo-
anovulation (O) and polycystic ovaries (P). According to the
1990 NIH criteria, the presence of both (1) oligo- and/or
anovulation and (2) clinical (hirsutism) and/or biochemical signs
of hyperandrogenism (H) are needed, regardless of the presence of
P on ultrasound [1]. The 2004 Rotterdam criteria suggest that PCOS
should be deﬁnedwhen at least two of the three features (O, H, and
P) are present, with the exclusion of other etiologies that mimic
PCOS [2].
PCOS is not only one of the main causes of infertility in women,
but it is also considered as a plurimetabolic syndrome. In fact, PCOS
is associated with long-term health risks, including insulin
resistance/diabetes mellitus, obesity, alterations of the ﬁbrinolytic
system and dyslipidemia. These cardiovascular risk factors may
often appear at an early age, suggesting that women with PCOS
represent a large group at an increased risk for developing early
onset cardiovascular disease (CVD) [3].
Therefore, PCOS is becoming a health care-related economic
burden, in regards to the annual cost of evaluating and providing
care to reproductive-aged women with PCOS in United States
exceeds $4.3billion [4].
In this review we will focus on obesity in PCOS, with emphasis




Weight gain and central obesity are common features of PCOS
and often precede the onset of anovulatory cycles. Visceral
adiposity in PCOS is associated with greater insulin resistance
(IR) resulting in exacerbation of the reproductive and metabolic
abnormalities. Moreover, obesity has a major impact on PCOS
phenotype since it is associated with a greater prevalence of
menstrual irregularity, hyperandrogenemia and hirsutism [5].
The prevalence of overweight and obese women in PCOS is
greater than that of the general female population. Conversely, the
prevalence of PCOS increased in obese and overweight women
compared to their lean counterparts. Alvarez-Blasco et al. [6]
reported a 28.3% prevalence rate of PCOS in 113 overweight or
obese women, who were referred to an endocrinology clinic for
weight loss, compared with a previously reported 6.5% prevalence
in the population [7], suggesting that the prevalence of PCOSmight
be markedly increased by obesity. In this study, the prevalence of
PCOS was not related to the severity of obesity and was
independent of the presence or absence of themetabolic syndrome
thus suggesting that PCOS is not necessarily associated with
obesity andmetabolic syndrome [7]. On the other hand, Yildiz et al.
[8] found that prevalence of PCOS was about 30% higher in
unselected reproductive-aged women compared to the general
population with moderate to severe obesity (12% vs. 9%), although
this did not reach statistical signiﬁcance. Moreover, the risk ofPCOS was shown to be minimally increased with obesity [8]. The
authors also reported that the degree of obesity of PCOS patients
increased over time similar to the general population over a 15-
year period, thus suggesting that obesity in PCOS is inﬂuenced by
environmental factors [8]. However, in a recent study by Yildiz
et al. [9], the prevalence rates of PCOS in obese women was found
to be 2-fold higher or 3-fold higher compared to non-obesewomen
according to the NIH or the Rotterdam criteria, respectively. In this
study the prevalence of obesity was reported to be 15% according
to Rotterdam criteria. This discrepancy may be due to different
enrollment criteria of populations. The proportion of overweight
PCOS women ranges from 10% in Italy to 37% in Kuwait, which
supports widespread variability in the prevalence of overweight
and obese women in PCOS populations among different countries.
The highest prevalence of obesity associated to PCOS (61–76%) has
been reported in the USA and Australia [10]. Ethnic origin also
plays a signiﬁcant role in the expression of features of PCOS,
including prevalence and severity of obesity and metabolic
disturbances. Asian women generally have been reported to have
shorter stature and lower BMI compared to South Asians, African
American and Hispanic women that displayed a higher prevalence
of central obesity and metabolic syndrome [11].
Adipocytokines
Adipose tissue is the largest endocrine organ in the human body
with many impacts on glucose homeostasis, steroid production,
immune competence, hematopoesis and reproductive function.
Adipose tissue produces a number of products including adipo-
kines that are peptides acting as cytokines, chemokines, growth
factors, and neurally active hormones. Some adipokines are
secreted into the circulation (e.g., leptin) whereas others such as
TNF-a function as paracrine or autocrine regulators. Several
adipokines such as leptin, adiponectin, IL-6, plasminogen activator
inhibitor (PAI) 1, visfatin, vaspin, resistin and TNF-a may play a
role in the pathogenesis of obesity-related insulin resistance and
also directly affect ovarian and adrenal function [12]. The exact
role of these adipokines in the pathophysiology of PCOS is still
unknown. The adipokines leptin and adiponectin, which play
major role in glucose metabolism, will be addressed here in detail.
Leptin
Leptin is a 167-amino acid polypeptide that is synthesized
predominantly by fat cells [14]. In a recent study by Lecke et al.
[17], serum leptin level and subcutaneous leptin messenger RNA
were found to be higher in overweight/obese PCOS women
compared to normal-weight controls, and the authors reported
that leptin/adiponectin ratio was signiﬁcantly associated with
percentage of body fat independent of BMI and free androgen
index. Leptin was found in follicular ﬂuid and leptin receptors are
localized in preovulatory follicle, mature oocyte, granulosa, theca
and interstitial cells. Elevated leptin levels are thought to be
associatedwith the lack of follicularmaturation. The concentration
of leptin receptors was found to be similar in granulosa cells of
PCOS women and of women undergoing in vitro fertilization for
tubal disease, but the level of phosphorylated signal transducer
and activator of transcription proteins was reported to be lower in
PCOS suggesting that leptin signaling is disrupted in PCOS
F. Orio et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 207 (2016) 214–219216[18]. Interestingly, in a recent study, it has been demonstrated that
administration of the hormone leptin as an insulin sensitizing
agent caused a reduction in testosterone levels and induced
menses in lean women with PCOS and lipodystrophy [19].
In conclusion, PCOS,mostlywhen it is associated to overweight/
obesity, is characterized by high levels of leptin, although the latter
seems to be ineffective due to disrupted lepting signaling.
Adiponectin
Adiponectin is a 30 kDa protein that is the most abundant
secreted adipokine from adipocytes. The potential role of
adiponectin in the ovulatory dysfunction and metabolic abnor-
malities in PCOS has been investigated in several studies.
Adiponectin at physiological levels induces expression of genes
such as cyclooxygenase-2, prostaglandin E synthase and vascular
endothelial growth factor, which are associated with periovu-
latory remodeling of the ovarian follicle. Plasma adiponectin
levels are found to be correlated with insulin sensitivity in PCOS,
independent of adiposity in some studies [20], whereas others
failed to demonstrate this association [21]. In a study by
Pangaribuan et al., it has been reported that serum adiponectin
levels were reduced in obese women with PCOS, and that BMI,
testosterone levels and IR were found to be major determinants
of hypoadiponectinemia [22]. In the recent studies, it was shown
that adiponectin affects the reproductive system through central
effects on the hypothalamus-pituitary axis and through periph-
eral effects on the ovary and uterus, or directly on the oocyte and
embryo. Adiponectin decreases LH secretion in pituitary
gonadotropes and increases the secretion of progesterone and
estradiol in human granulosa cells through an increase in p450
aromatase.
Genome-wide scan and linkage studies about the adiponectin
gene reported a susceptibility locus for obesity, T2 DM and
coronary artery disease. Particularly, two single nucleotide
polymorphisms (SNPs), i.e. +45G15G(T/G) and +276(G/T), in exon
2 and intron 2 of the ADIPOQ gene (adipocyte C1q and collagen
domain containing) respectively, were found to be strongly
associated with T2DM, obesity and IR [23]. There is still
controversy regarding the role of adiponectin gene polymorphism
in women with PCOS. Zhang et al. [24] reported a higher
prevalence of the +45G and +276G/T polymorphism in the
adiponectin gene in women with PCOS compared to controls,
while other studies failed to show this association [25]. Moreover,
studies upon the effects of oral contraceptives or insulin sensitizers
on adiponectin levels demonstrated that both adiponectin levels
and insulin-stimulated glucose disposal increased when PCOS
patients were treated with metformin or pioglitazone [26] while
oral contraceptives caused a decrease in adiponectin levels [26].
In conclusion adiponectin could be considered as a marker of IR
in PCOS. In fact adiponectin has been found to correlate with
insulin sensitivity. Low adiponectin levels in PCOS contribute to
increase cardiovascular risk.
PCOS in obesity
PCOS is a very commonﬁnding in obesewomen [27]. Azziz et al.
estimated the prevalence of the different pathological conditions
causing clinically evident androgen excess in a large consecutive
population of patients. They found that 82% of the enrolled women
were affected by PCOS and all the women affected by PCOS were
obese [28]. Cupisti et al. performed a study in the same Azziz’s
experimental setting aiming to evaluate associations of clinical
features, such as hirsutism, polycystic ovaries (PCOs), ovulatory
dysfunction, and body mass index (BMI) R25 kg/m2, with
metabolic abnormalities in hyperandrogenic women. The resultscoming from this study showed that PCOS was a common ﬁnding
in obese/overweight women [29]. Higher levels of BMI were
associated to PCOS also in a study performed in three tundre forty
women with hirsutism as the referral diagnosis [30]. German
women with metabolic syndrome have been found to be affected
by PCOS in 33% of cases [31].
Based on these data reporting the frequent association between
obesity and PCOS, it could be suggested that screening for PCOS
should be considered in obese women, mostly when they referred
menstrual irregularities.
Type 2 diabetes mellitus and PCOS
Deﬁnition and diagnosis
IR is present in 50–80% of these women. IR is associated with
obesity, but even lean PCOS womenmay have IR, that is secondary
to a genetic disorder of insulin action. IR and pancreatic b-cell
dysfunction are important risk factors for the development of
T2DM in PCOS. This metabolic condition exists before puberty
contributing to androgen excess state since compensatory
hyperinsulinemia induces androgen secretion at the level of
ovaries. On the other hand, it has been suggested that a state of
excessive androgen secretion during fetal life might contribute to
IR in PCOS patients by causing abdominal distribution of body fat
and visceral adipose tissue dysfunction.
More than 2% of PCOS women have a risk of developing
diabetes each year. To prevent metabolic and cardiovascular
disease risk in women with PCOS, screening for these factors
should start as early as possible and even at diagnosis. It has been
suggested that BMI,WCand bloodpressure should bemeasured at
each visit. Women with PCOS have postprandial hyperglycemia
most commonly reﬂecting peripheral IR. Therefore, 2-h post-
challenge glucose values are suggested for the diagnosis of IGT
and T2DM in PCOS. The AE-PCOS Society recommends that
screening should be performed in obese patients or in lean
patients with advanced age (>40 years) and patients with a
history of gestational diabetes orwith a family history of diabetes.
The recommended initial screening test is either fasting plasma
glucose or 75 g oral glucose tolerance test (OGTT) [32]. Recently,
the AmericanDiabetes Association (ADA) has included the level of
glycated hemoglobin A1c (HbA1c) as a component of the
diagnostic criteria for ‘diabetes’ (6.5% HbA1c) or ‘increased risk
for diabetes’ (5.7–6.4% HbA1c). In agreement with ADA recom-
mendations [33], the AE-PCOS society also included the HbA1c
criteria for assessment of diabetes in PCOS. The measurement of
HbA1Chas several advantages compared to the FPGandOGTT that
include greater convenience (fasting not required), greater
preanalytical stability and less day-to-day variations during
stress and illness. However, the use of HbA1C is limited by greater
cost, the limited availability of HbA1C testing in certain regions of
the developing world and the partial correlation between HbA1C
and average glucose in certain individuals. The most appropriate
time interval for re-screening of women with PCOS is also
controversial. The ADA recommends diabetes screening for high
risk patients including women with PCOS at least every 3 years,
whereas some other organizations recommend re-screening
every 1–2 years depending on the presence of co-existing risk
factors.
Risk
The risk of development of IGT and T2DM in PCOS is
investigated in many small-size studies. Legro et al. [34] failed
to ﬁnd a signiﬁcant increase in the prevalence of IGT and T2DM
from 37% to 45%, and from 10% to 15%, respectively, over a mean
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23 controls. The authors did not ﬁnd an association with weight
gain. They also reported that nonobese PCOSwomen (BMI < 27 kg/
m2) were also at high risk of glucose intolerance (10.3 and 1.5%
prevalence of IGT and T2DM, respectively). Another study
including 67 overweight Australian women with PCOS, with a
longer follow-up time (mean 6.2 years) reported an annual
incidence of T2DM of approximately 2.5% [35]. In contrast, weight
gain was found to be a predictor of glucose derangements in this
study [35]. In a recently reported larger size study, including
21,170 women with PCOS and 89,636 controls matched for age,
primary-care practice and BMI, it has been demonstrated that the
incidence of T2DM was increased in PCOS compared to controls
after a median follow-up period of 5 years [36]. BMI was found to
have an important role in the development of diabetes, and with
increasing BMI, a nonsigniﬁcant trend toward an increased crude
rate of diabetes was also reported. Consistent with the ﬁndings of
Legro et al. [34], the risk for the development of diabetes was
signiﬁcantly higher in the lean subgroup (hazard ratio: 1.4 for
BMI < 25 kg/m2 [4_TD$DIFF]). Weight gain was also reported to be associated
with worsening glucose tolerance and a 1% increase in BMI lead to
2% increase in diabetes risk. The risk of diabetes was found to be
higher in patients who were obese at baseline and remained obese
for at least 2 years. The authors failed to show any association with
the development of diabetes and the treatment with oral contra-
ceptives or antiandrogens despite the reports that these may
worsen insulin sensitivity [36]. Further, Mo¨hlig et al. reported that
the increased risk of diabetes associated to PCOSwas not related to
the endocrinological features of the syndrome but it was related to
overweight/obesity that often accompanied this disease [37]. In
contrast, metformin was found to be associated with an increased
risk of diabetes, but this was linked to preferential prescribing to a
population with more frequent insulin resistance, higher BMI and
more frequent risk factors such as family history or previous
gestational diabetes [36]. On the other hand, it is known that
metformin reduces IR in women with PCOS and that it may reduce
the conversion rate from normal glucose tolerance to IGT and
T2DM in this population.
The prevalence of glucose derangements in PCOS may be also
inﬂuenced by the different diagnostic criteria that were used.
Patients diagnosed by the 1990 NIH classic criteria show higher
rate of menstrual irregularity, hyperandrogenism, abdominal
obesity and IR than those deﬁned by non-NIH criteria. The
prevalence of obesity and IRwas found to be greater in classic PCOS
patients than in those with ovulatory PCOS. Lifestyle modiﬁcations
seem to play a key role in themanagement of glucose disturbances.
A systematic review and meta-analysis including 9 trials enrolling
583 women suggested that lifestyle modiﬁcations decreased
fasting blood glucose and insulin levels in women with PCOS
and the obtained results were similar to the administration of
metformin [38].
Different prevalence according to ethnicity
Women affected by PCOS have increased risk for developing
T2DM and pre-diabetes (i.e., impaired fasting glucose (IFG) or
impaired glucose tolerance (IGT)) independent of BMI and age.
The prevalence of hyperglycemia is increased with BMI, being
highest in obese PCOS women (BMI > 30 kg/m2). However, even
lean women with PCOS have increased risk of IGT and T2DM [24].
11–35% of PCOS patients are reported to have IGT and from 4% to
10% of the patients are reported to have T2DM [26,39,40]. The
prevalence rate of IGT in PCOS was reported to be 3-fold higher
than thepopulationprevalence rate of IGT inwomenof similar age
from the National Health and Nutrition Survey (NHANES) II, and
twice the prevalence rate of IGT in age- and weight comparablereproductively normal control women [39]. Moreover, the
prevalence rate of undiagnosed T2DM was found to be from
7.5 to 10-fold higher than the prevalence rate in NHANES II
women of similar age [39]. The development of diabetes in PCOS
may be signiﬁcantly impacted by differences in population
characteristics in studies from different countries. The prevalence
of IGT and T2DM were as low as 6.4% and 0–2.3%, respectively, in
two small Italian and Dutch studies [41,42].
In conclusion PCOS currently represents a risk factor for
developing type 2 diabetes. Lean PCOS displayed the same degree
of IR of overweight/obese healthy women, thus suggesting that IR
is a common feature of PCOS. Based on these considerations, it is
easy to understand the beneﬁcial effects of metformin in the
treatment of PCOS.
Cardiovascular disease risk and PCOS
Multiple risk factors for CVD including obesity, IR, dyslipidemia,
arterial hypertension, coagulation disorders and hyperandrogen-
ism may be found in young women with PCOS, although evidence
for cardiovascular events in women with PCOS is limited.
Obesity, in particular, central obesity, contributes to worsen
metabolic phenotype in PCOS. As it is well known, central obesity is
involved in the secretion of several hormones and cytokines
contributing to the onset of a proinﬂammatory state and oxidative
damage that in turn, lead to endothelial dysfunction and to
initiation and progression of atherosclerosis. Moreover, visceral fat
plays a key role in the development of IR and lipid metabolism
disorders. IR is very common in PCOS patients, occurring in
approximately 60–80% of lean and 95% of obese womenwith PCOS
[43]. IR is related to IGT and metabolic syndrome, two other
predictors of T2DM and CVD [44]. A consequence of IR is an
atherogenic lipoprotein proﬁle, characterized by hypertriglycer-
idemia, increased low-density lipoprotein cholesterol (LDL-C)
levels and decreased high-density lipoprotein cholesterol (HDL-
C) levels. The impaired ability of insulin to suppress lipolysis
increases mobilization of free fatty acids from adipose stores to
liver, hampering insulin-mediated inhibition of hepatic very low-
density lipoprotein cholesterol (VLDL-C) synthesis and blunting
catabolism of VLDL-C [45]. Several studies examined the relation-
ship of PCOS with dyslipidemia. In a study comparing womenwith
PCOS to controls, higher LDL-C and lower HDL-C levels were found
in PCOSwomen [46]. The association of PCOS and hypertension has
been investigated, but controversial results have been reported. An
increased prevalence of hypertension was described in obese PCOS
patients [47], whereas it was not noticed in the lean PCOS [48],
suggesting that obesity may be a confounding factor and the main
determinant of hypertension in PCOS. Coagulation disorders
constitute a risk factor for CVD. The association between
coagulation disorders and PCOS provided conﬂicting results.
Dahlgren et al. studied the coagulation proﬁle in 28 PCOS women
matched with 56 controls and they did not ﬁnd any signiﬁcant
difference in term of PAI-1, vWF and factor VII activity
[49]. Conversely, Yildiz et al. found an impairment of ﬁbrinolysis
in PCOS, reﬂected by the decrease of the global ﬁbrinolytic
capacity, that was not related to IR, therefore suggesting a
protrombotic state in PCOS [50]. Lastly hyperandrogenism in
itself may play a role in worsening IR and in the simultaneous
development of central obesity in PCOS.
Low-grade chronic inﬂammation has also been implicated in
the pathogenesis of cardiovascular disease risk in PCOS. Several
markers of inﬂammation such as C reactive protein (CRP),
ﬁbrinogen and white blood cell count were found to be
signiﬁcantly increased in PCOS [51]. Moreover, CRP was found
to be closely related to the degree of visceral fat accumulation. A
direct correlation between CRP levels and aldosteronewas found in
[(Fig._1)TD$FIG]
Fig. 1. Pathogenesis of cardiovascular disease in polycystic ovarian syndrome. Polycystic ovarian syndrome (PCOS) has been identiﬁed as a risk factor for cardiovascular
disease. The multiple risk factors for cardiovascular disease that are associated with PCOS include type 2 diabetes, dyslipidemia, arterial hypertension, low grade chronic
inﬂammation, increased leptin levels, decreased adiponectin levels and coagulation disorders.
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followed by necrosis and subsequent reparative ﬁbrosis inducing
oxidative/nitrosative stress [52]. Acute phase reactants (CRP,
ﬁbrinogen and white blood cell count) were found to be
independently associated with a direct measure of cardiorespira-
tory ﬁtness (VO2max) in 124 PCOS women suggesting that
cardiopulmonary capacity may be strongly related to low grade
inﬂammation in PCOS [53]. However, evidence of increased
cardiovascular morbidity and mortality is inconsistent in PCOS.
No increased prevalence of non-fatal/fatal cardiovascular events
in PCOSwas found in the report byPierpoint et al. [54]. Conversely,
the Women’s Ischemia Evaluation Study reported that PCOS
women had an increased prevalence of cardiovascular events, and
in particular multivessel diseases, compared to non-PCOSwomen
[55]. In support of this study, a greater coronary artery
calciﬁcation prevalence was found in PCOS compared to controls
in two studies [56]. Birdsall et al. found evidence of more
advanced coronary artery diseases in PCOS women than women
with normal ovaries, among 143 women undergoing coronary
angiography for chest pain or valvular diseases. In addition to
overt CVD, women with PCOS have evidence of more frequent
subclinical vascular diseases vs. controls [57]. Early endothelial
impairment was found by Orio et al. in 30 young normal-weight
women with PCOS, who had no additional metabolic disorders or
CVD. In particular, abnormal media thickness of carotid arteries,
abnormal ﬂow mediated dilation of brachial arteries and higher
levels of plasma endothelin-1 were found in PCOS [58] (Fig. 1).
These results have been recently emphasized by a meta-analysis
that reported an impaired endothelial function as measured by
ﬂow-mediated dilation of the brachial artery, already at an early
age [59]. A cross-sectional analysis using Truven Health Analytics
MarketScan1 Commercial databases from 2004 to 2011 assessed
the association between women aged 18–64 years with and
without PCOS and cardiovascular events.Womenwith PCOSwere
more likely to have aCVD, with stroke being the most prevalent
manifestation [60].
In conclusion PCOS is associated to an increased cardiovascular
risk. This is related to several factors. First, IR could be considered
an important player in the pathogenesis of dyslipidemia associated
to PCOS. Controversial results on the association of PCOS with
hypertension have been reported while it seems to be a clear link
between PCOS and early cardiovascular derangements such as
endothelial dysfunction.Conclusion
PCOS has been often associated to overweight/obesity and in
turn PCOS is a common ﬁnding in overweight/obese subjects.
Adipose tissue plays an important role in determining metabolic
features of PCOS. In fact it has been demonstrated that the
secretion of ‘‘metabolic’’ hormones such as leptin and adiponectin
is modiﬁed in PCOS, respectively increasing and decreasing. This
contributes to metabolic derangements associated to PCOS. The
spectrum growing from insulin resistance to type 2 diabetes is
commonly associated to PCOS, contributing to the increased
cardiovascular risk identiﬁed as a risk factor for obesity, T2DM and
CVD. Large-scale clinical trials evaluating the morbidity and
mortality of CVD in PCOS subjects are lacking. Further, well-
designed prospective controlled studies are still needed in order to
predict the long term risk of developing T2DM and CVD. However,
a careful metabolic and cardiovascular assessment is advisable in
women with PCOS[1_TD$DIFF].
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